CN114767877B - 石墨烯基材料于制备延缓衰老的药物中的用途 - Google Patents
石墨烯基材料于制备延缓衰老的药物中的用途 Download PDFInfo
- Publication number
- CN114767877B CN114767877B CN202210432582.5A CN202210432582A CN114767877B CN 114767877 B CN114767877 B CN 114767877B CN 202210432582 A CN202210432582 A CN 202210432582A CN 114767877 B CN114767877 B CN 114767877B
- Authority
- CN
- China
- Prior art keywords
- graphene
- based material
- aging
- polypyrrole
- life
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 title claims abstract description 58
- 229910021389 graphene Inorganic materials 0.000 title claims abstract description 57
- 239000000463 material Substances 0.000 title claims abstract description 52
- 239000003814 drug Substances 0.000 title claims abstract description 13
- 230000003712 anti-aging effect Effects 0.000 title claims abstract description 11
- 229940079593 drug Drugs 0.000 title abstract description 8
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 claims abstract description 36
- 229920000128 polypyrrole Polymers 0.000 claims abstract description 29
- 239000002184 metal Substances 0.000 claims abstract description 13
- 229910052751 metal Inorganic materials 0.000 claims abstract description 13
- 229910052763 palladium Inorganic materials 0.000 claims abstract description 13
- 239000002245 particle Substances 0.000 claims abstract description 12
- 238000002474 experimental method Methods 0.000 abstract description 4
- 230000032683 aging Effects 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- 239000000243 solution Substances 0.000 description 6
- 238000000034 method Methods 0.000 description 5
- 230000002438 mitochondrial effect Effects 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 239000002086 nanomaterial Substances 0.000 description 3
- 230000009758 senescence Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 2
- 230000006399 behavior Effects 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000002131 composite material Substances 0.000 description 2
- 230000004898 mitochondrial function Effects 0.000 description 2
- 230000034958 pharyngeal pumping Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 238000012876 topography Methods 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 description 1
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 description 1
- 235000009754 Vitis X bourquina Nutrition 0.000 description 1
- 235000012333 Vitis X labruscana Nutrition 0.000 description 1
- 235000014787 Vitis vinifera Nutrition 0.000 description 1
- 240000006365 Vitis vinifera Species 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000002073 fluorescence micrograph Methods 0.000 description 1
- 238000000799 fluorescence microscopy Methods 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 238000011112 process operation Methods 0.000 description 1
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 235000021283 resveratrol Nutrition 0.000 description 1
- 229940016667 resveratrol Drugs 0.000 description 1
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 1
- 229960002930 sirolimus Drugs 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6923—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/44—Elemental carbon, e.g. charcoal, carbon black
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Ceramic Engineering (AREA)
- Carbon And Carbon Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明公开了一种石墨烯基材料于制备延缓衰老的药物中的用途。所述石墨烯基材料包括金属钯颗粒、氧化石墨烯及聚吡咯，所述金属钯颗粒通过聚吡咯的桥连附着于氧化石墨烯表面。本发明提出石墨烯基材料可用于制备延缓衰老的药物，通过实验证明石墨烯基材料可以显著延长蠕虫的寿命。
Description
技术领域
本发明属于医药技术领域，具体涉及一种石墨烯基材料于制备延缓衰老的药物中的用途。
背景技术
衰老是每个人都逃脱不了的宿命，但借助现代医疗技术手段，人类有望对抗衰老，大幅延长寿命的方法。为此科学家们提出了各种方案：一些尖端科学研究正在分析一些可延长寿命的化学分子的原理，其中包括：白藜芦醇(葡萄中的一种物质)、雷怕霉素(源自复活岛细菌)和p21基因蛋白质；日本和美国研究人员合作的一项最新研究，血液中一种名为“eNAMPT”的酶与寿命及健康状况相关，将从年轻鼠血液中提取的这种酶注射到年长鼠体内能显著延长后者寿命。但在过去的大量研究中，主要使用化学分子药物、酶或基因工程。这些技术要么环境要求高、要么技术复杂难以操作且效果不显著。因此亟待开发出效果显著延缓衰老和延长寿命的纳米材料。
发明内容
本发明的主要目的在于提供一种石墨烯基材料于制备延缓衰老的药物中的用途，以克服现有技术的不足。
为实现前述发明目的，本发明采用的技术方案包括：
本发明实施例提供了石墨烯基材料于制备延缓衰老的药物中的用途，所述石墨烯基材料包括金属钯颗粒、氧化石墨烯及聚吡咯，所述金属钯颗粒通过聚吡咯的桥连附着于氧化石墨烯表面。
本发明实施例还提供了一种具有延缓衰老功能的产品，所述产品包括石墨烯基材料，所述石墨烯基材料包括金属钯颗粒、氧化石墨烯及聚吡咯，所述金属钯颗粒通过聚吡咯的桥连附着于氧化石墨烯表面。
本发明实施例还提供了一种试剂盒，所述试剂盒包括前述的石墨烯基材料。
与现有技术相比，本发明的有益效果在于：本发明提出石墨烯基材料可用于制备延缓衰老的药物，通过实验证明，石墨烯基材料可以显著延长蠕虫的寿命。
附图说明
为了更清楚地说明本发明实施例或现有技术中的技术方案，下面将对实施例或现有技术描述中所需要使用的附图作简单地介绍，显而易见地，下面描述中的附图仅仅是本发明中记载的一些实施例，对于本领域普通技术人员来讲，在不付出创造性劳动的前提下，还可以根据这些附图获得其他的附图。
图1a-图1b是本发明实施例1中石墨烯基材料的透射电子显微镜形貌图；
图2是本发明实施例1中不同剂量的Pd@PPy/GO的对蠕虫寿命延长效果图；
图3是本发明一典型实施方案中GO、PPy/GO、Pd@PPy/GO不同材料的对蠕虫寿命延长效果图。
图4是本发明实施例1中利用不同材料投喂的蠕虫荧光成像照片，主要显示不同材料投喂后蠕虫线粒体密度变化。
具体实施方式
鉴于现有技术的缺陷，本案发明人经长期研究和大量实践，得以提出本发明的技术方案，下面将对本发明的技术方案进行清楚、完整地描述，显然，所描述的实施例是本发明一部分实施例，而不是全部的实施例。基于本发明中的实施例，本领域普通技术人员在没有做出创造性劳动前提下所获得的所有其他实施例，都属于本发明保护的范围。
具体的，作为本发明技术方案的一个方面，其所涉及的石墨烯基材料于制备延缓衰老的药物中的用途，所述石墨烯基材料(亦记为“Pd@PPy/GO”)包括金属钯颗粒、氧化石墨烯及聚吡咯，所述金属钯颗粒通过聚吡咯的桥连附着于氧化石墨烯表面。
本发明中的石墨烯基材料可采用专利CN113077919A中所述的金属Pd负载的石墨烯/聚吡咯复合材料。
在一些优选实施方案中，所述石墨烯基材料的尺寸为50～200nm。
进一步地，所述石墨烯基材料的尺寸为200nm。
在一些优选实施方案中，所述石墨烯基材料可以延长生物体的寿命。
进一步地，所述生物体可以是蠕虫。
本发明中评价石墨烯基材料的延缓衰老的效用的实验具体包括：将含有一定浓度石墨烯基材料的培养液投喂一定数量的蠕虫，每2天，评价蠕虫行为，当蠕虫停止咽泵和对触摸无反应时被评分为死亡，从而评价石墨烯基材料延缓衰老的效用。
进一步地，延缓衰老实验包括：在含有20-200个接种了100μL大肠杆菌OP50菌株的微米酵母的NGM平板上检测。
进一步地，蠕虫的数量为50-150只/组，分为3-8组。
进一步地，石墨烯基材料混合在培养基中，蠕虫投喂的石墨烯基材料质量范围为0.1-100μg/mL。
本发明实施例的另一个方面还提供了一种具有延缓衰老功能的产品，其特征在于，所述产品包括石墨烯基材料，所述石墨烯基材料包括金属钯颗粒、氧化石墨烯及聚吡咯，所述金属钯颗粒通过聚吡咯的桥连附着于氧化石墨烯表面。
在一些优选实施方案中，所述石墨烯基材料的尺寸为50～200nm。
进一步地，所述石墨烯基材料的尺寸为200nm。
在一些优选实施方案中，所述石墨烯基材料可以延长生物体的寿命。
进一步地，所述生物体可以是蠕虫。
本发明实施例的另一个方面还提供了一种试剂盒，所述试剂盒包括权利要求1-3中任一项所述的石墨烯基材料。
下面结合若干优选实施例及附图对本发明的技术方案做进一步详细说明，本实施例在以发明技术方案为前提下进行实施，给出了详细的实施方式和具体的操作过程，但本发明的保护范围不限于下述的实施例。
下面所用的实施例中所采用的实验材料，如无特殊说明，均可由常规的生化试剂公司购买得到。
实施例1
石墨烯基材料作为延缓衰老药物包括如下步骤：分别将含有一定浓度石墨烯基材料(0.5μg/mL、5μg/mL和50μg/mL)的培养液投喂一定数量(80只/组)的蠕虫，每2天，评价蠕虫行为，当蠕虫停止咽泵和对触摸无反应时被评分为死亡，从而评价石墨烯基材料延缓衰老和延长寿命的效用。同时对比不同材料投喂的蠕虫寿命结果，从而证明本发明中的石墨烯基材料(Pd@PPy/GO)具有明显优异性。通过机制研究，发现Pd@PPy/GO投喂的蠕虫其线粒体密度，明显比其他材料投喂蠕虫的线粒体密度偏高。由此可见Pd@PPy/GO延缓衰老功能和其影响生物体线粒体功能密切相关。
图1a-图1b是本实施例中石墨烯基材料的的透射电子显微镜形貌图，从图1a-图1b中可以看出1-3nm的钯纳米颗粒均匀的附着在片状的氧化石墨烯表面，这种附着是通过聚吡咯的桥连实现的。
图2为本实施例中不同剂量的Pd@PPy/GO的对蠕虫寿命延长效果图，发现不同剂量的Pd@PPy/GO都能够延长蠕虫的寿命。
图3为空白、GO、PPy/GO、Pd@PPy/GO(0.5μg/mL)不同材料的对蠕虫寿命延长效果图，发现Pd@PPy/GO对蠕虫寿命延长效果最佳，可以延长14.3％的蠕虫寿命。
图4是利用不同材料投喂的蠕虫荧光成像照片，主要显示不同材料投喂后蠕虫线粒体密度变化。从结果发现Pd@PPy/GO投喂的蠕虫其线粒体密度，明显比其他材料投喂蠕虫的线粒体密度偏高。由此可见Pd@PPy/GO延缓衰老功能和其影响生物体线粒体功能密切相关。
对比例1
将石墨烯(GO)纳米材料和聚吡咯石墨烯复合纳米材料(PPy/GO)(浓度均为0.5μg/mL)作为延缓衰老药物，方法同实施例1。其对蠕虫寿命延长效果如图3所示，相较于实施例1延缓衰老效果明显下降。
此外，本案发明人还参照前述实施例，以本说明书述及的其它原料、工艺操作、工艺条件进行了试验，并均获得了较为理想的结果。
应当理解，本发明的技术方案不限于上述具体实施案例的限制，凡是在不脱离本发明宗旨和权利要求所保护的范围情况下，根据本发明的技术方案做出的技术变形，均落于本发明的保护范围之内。
Claims (2)
1.石墨烯基材料于制备延缓衰老的药物中的用途，所述石墨烯基材料包括金属钯颗粒、氧化石墨烯及聚吡咯，所述金属钯颗粒通过聚吡咯的桥连附着于氧化石墨烯表面，所述石墨烯基材料的尺寸为50~200nm。
2.根据权利要求1所述的用途，其特征在于：所述石墨烯基材料能够延长生物体的寿命。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210432582.5A CN114767877B (zh) | 2022-04-22 | 2022-04-22 | 石墨烯基材料于制备延缓衰老的药物中的用途 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210432582.5A CN114767877B (zh) | 2022-04-22 | 2022-04-22 | 石墨烯基材料于制备延缓衰老的药物中的用途 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN114767877A CN114767877A (zh) | 2022-07-22 |
| CN114767877B true CN114767877B (zh) | 2023-11-03 |
Family
ID=82433770
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210432582.5A Active CN114767877B (zh) | 2022-04-22 | 2022-04-22 | 石墨烯基材料于制备延缓衰老的药物中的用途 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114767877B (zh) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111175277A (zh) * | 2020-01-09 | 2020-05-19 | 徐州医科大学 | 用于检测阿尔兹海默病生物标记物的检测试剂、试剂盒、制备方法和检测方法 |
| CN112933112A (zh) * | 2021-02-09 | 2021-06-11 | 徐州医科大学附属医院 | 氧化石墨烯或其调控分子在制备促进糖尿病创面修复的药物中的应用 |
| CN113077919A (zh) * | 2021-03-25 | 2021-07-06 | 徐州医科大学 | 金属Pd负载的石墨烯/聚吡咯复合材料及其制法与应用 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10786573B2 (en) * | 2012-10-04 | 2020-09-29 | University of Pittsburgh—of the Commonwealth System of Higher Education | Conductive polymer graphene oxide composite materials |
| US11219892B2 (en) * | 2017-10-06 | 2022-01-11 | Virginia Commonwealth University | Carbon based materials as solid-state ligands for metal nanoparticle catalysts |
-
2022
- 2022-04-22 CN CN202210432582.5A patent/CN114767877B/zh active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111175277A (zh) * | 2020-01-09 | 2020-05-19 | 徐州医科大学 | 用于检测阿尔兹海默病生物标记物的检测试剂、试剂盒、制备方法和检测方法 |
| CN112933112A (zh) * | 2021-02-09 | 2021-06-11 | 徐州医科大学附属医院 | 氧化石墨烯或其调控分子在制备促进糖尿病创面修复的药物中的应用 |
| CN113077919A (zh) * | 2021-03-25 | 2021-07-06 | 徐州医科大学 | 金属Pd负载的石墨烯/聚吡咯复合材料及其制法与应用 |
Non-Patent Citations (4)
| Title |
|---|
| Wenshu Cong等.Mitochondrial-mimicking nanozyme-catalyzed cascade reactions for aging attenuation.Nano Today.2023,第48卷 * |
| 夏辉明等.《医学前沿》.人民卫生出版社,1993,第224页第4段. * |
| 张秀明等.《现代临床生化检验学》.人民军医出版社,2001,第911页左栏第4段. * |
| 陈金峰等.过氧化氢酶在衰老和疾病调控中的作用机制.医学分子生物学杂志.2007,第4卷(第3期),第276-278页. * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN114767877A (zh) | 2022-07-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Arun et al. | Green synthesis of silver nanoparticles using the mushroom fungus Schizophyllum commune and its biomedical applications | |
| Zhang et al. | Semicontinuous culture of Magnetospirillum gryphiswaldense MSR-1 cells in an autofermentor by nutrient-balanced and isosmotic feeding strategies | |
| Vazquez-Nin et al. | Comparative ultrastructural study of perichromatin-and Balbiani ring granules | |
| CN108480650B (zh) | 一种液态金属纳米颗粒及其制备方法 | |
| Nazari et al. | The antimicrobial effects and metabolomic footprinting of carboxyl-capped bismuth nanoparticles against Helicobacter pylori | |
| CN111304133B (zh) | 一种培养嗜黏蛋白阿克曼氏菌的培养基及其使用方法和应用 | |
| Bagyalakshmi et al. | A Zno nanorods based enzymatic glucose biosensor by immobilization of glucose oxidase on a chitosan film | |
| Bitew et al. | Recent reports on electrochemical determination of selected antibiotics in pharmaceutical formulations: A mini review | |
| Xu et al. | Fabrication of magnetic porous pseudo-carbon paste electrode electrochemical biosensor and its application in detection of schistosoma egg antigen | |
| Fan et al. | Controllable synthesis of CdSe nanostructures with tunable morphology and their application in DNA biosensor of Avian Influenza Virus | |
| CN114767877B (zh) | 石墨烯基材料于制备延缓衰老的药物中的用途 | |
| Malik et al. | Biodesulphurization of coal: effect of pulse feeding and leachate recycle | |
| CN101041431A (zh) | 一种氮和过渡金属元素掺杂的碳纳米颗粒的制备方法 | |
| Sachivkina et al. | Efficiency of lyticase (bacterial enzyme) in experimental candidal vaginitis in mice | |
| Hata et al. | Nanospiked paper: microfibrous cellulose materials nanostructured via partial hydrolysis and self-assembly | |
| CA2947570C (en) | Treatment of vaginitis | |
| Wu et al. | Biological Applications of Graphene and Graphene Oxide. | |
| Szala et al. | Toxicity assessment of SiC nanofibers and nanorods against bacteria | |
| CN114686395A (zh) | 一种枯草芽孢杆菌及应用其产纳米硒的方法 | |
| Taniguchi et al. | Pulmonary Nocardia otitidiscaviarum infection in a patient with chronic respiratory infection | |
| Sancho et al. | Optimization of growth conditions for Magnetospirillum magnetotacticum and green synthesis of metallic nanoparticles | |
| CN111996137A (zh) | 一株植物乳杆菌 | |
| Xiao-He et al. | Performance and mechanism of screen-printed carbon paste electrode glucose biosensors based on functional carbon black | |
| Ahmed et al. | Characterization and antibacterial activity of biogenic iron nanoparticles using Proteus mirabilis | |
| CN1090602A (zh) | 绿脓杆菌msha菌毛株及其建立 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |